SPECIALIZED IN ANTIVIRAL SOLUTIONS

Human Rhinovirus

The NTVIRIN have accomplished to cure the RHINOVIRUSES DISEASES and the efficacy of the drug have found to be 73.1 PERCENT on in –vitro experiments. The formulated NTVIRIN has tested against HUMAN RHINOVIRUSES-17 and NTVIRIN shown better activities when it is compared with Ribavirin, as a standard. The efficacy of the NTVIRIN has evaluated by MTT assay method. A series of NTVIRIN solution concentrations in terms of µM/ml have treated against the HUMAN RHINOVIRUS-17 strains. The Anti-viral activities of the NTVIRIN Solutions increased on the course of 72 hours on viral strains and the drug shown 73.1PERCENT ANTI-VIRAL ACTIVITIES. The IC50 of NTVIRIN was observed at 26.22 µM/ml.

MARKET STRATEGY OF HRV PHARMACEUTICALS

Rhinoviruses (RVs) are the most common cause of the common cold. They chiefly cause upper respiratory tract infections (URTIs) but may infect the lower respiratory tract. Potential complications of infection include otitis media, sinusitis, chronic bronchitis, and exacerbations of reactive airway disease such as asthma. Although rhinovirus infections occur year-round, the incidence is highest in the fall and the spring. Manifestations of rhinovirus infection typically appear after an incubation period of 12-72 hours and last 7-11 days, but may persist for longer. The Rhinovirus causes HEADACHE, LOSS OF SENSE OF SMELL & TASTE, COUGH (30%) OF INFECTED INDIVIDUALS), HOARSENESS (20%), A red nose with a profuse, dripping nasal discharge may be present, Nasal discharge can be clear and watery or mucopurulent (yellow or green). Rhinoviruses are the most common of these (25-80% of cases), followed by coronaviruses (10- 20%), influenza viruses (10-15%), and adenoviruses (5%).
The rhinovirus infection drug market is RELATIVELY LARGE AND IS EXPANDING AS THE GLOBAL POPULATION INCREASES and the incidence of rhinovirus infection increases.

According to market research institutions, the size of the rhinovirus infection drug market will continue to grow in the next few years. The global upper respiratory tract infection treatment market was valued at USD 1.8 billion in 2022, driven by the increasing prevalence of upper respiratory tract infection across the globe.

The market size is anticipated to grow at a CAGR of 3.5% during the forecast period of 2023-2031 to achieve a value of USD 2.4 billion by 2031.

NTVIRIN ANTI-HRV PHARMACEUTICALS

Human Rhinoviruses-17 (RVs) are members of the Picornaviridae family, which includes the human pathogens Enterovirus and Hepatovirus (notably, hepatitis A virus). The common cold is an acute respiratory tract infection (RTI) around 66- 75% of cases are due to 200 antigenically distinct viruses from 8 different genera.
At present analgesics, cough suppressants, decongestants, or antihistamines are recommended for patients. Hoverer. infant children who have younger than SIX-year-old have been mostly affected due to Rhinoviruses infections. The FDA recommends against the use of over-the-counter cough and cold medicines in children younger than 2 years. Viruses don’t respond to antibiotics. Virus infected patients can mostly be treated through pain relievers, rest and drinking fluids. The NTVIRIN therapeutics have Zero-cytotoxic & causes no side effects and thus unique to cover all sub classes of HUMAN RHINOVIRUSES.

Common Cold

NTVIRIN Sinusitis

NTVIRIN Common Cold

The common cold is an illness affecting nose and throat. Most often, it’s harmless, but it might not feel that way. Germs called viruses cause a common cold. Often, adults may have two or three colds each year. Infants and young children may have colds more often. Most people recover from a common cold in 7 to 10 days. Symptoms might last longer in people who smoke. Illnesses of the nose and throat caused by germs are called upper respiratory tract infections

  • Sinusitis is an inflammation, or swelling, of the tissue lining sinuses.
  • Sinuses are structures inside the face that are normally filled with air.
  • Bacterial infections, viral infections and allergies can irritate them, causing them to get blocked and filled with fluid.
  • This can cause pressure and pain to the entire face, nasal congestion or a stuffy nose and other symptoms.
  • Sinusitis is also sometimes called RHINOSINUSITIS.

NTVIRIN Chronic Bronchitis

Chronic bronchitis is a type of COPD (Chronic Obstructive Pulmonary Disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. Chronic bronchitis is inflammation (swelling) and irritation of the bronchial tubes. These tubes are the airways that carry air to and from the air sacs in the lungs. The irritation of the tubes causes mucus to build up. This mucus and the swelling of the tubes make it harder for your lungs to move oxygen in and carbon dioxide out of your body. The cause of chronic bronchitis is usually long-term exposure to irritants that damage the lungs and airways.

Exacerbations of reactive airway disease

Reactive airway disease (RAD) is a term that healthcare providers use to describe breathing symptoms that are similar to ASTHMA, but they’re not sure of the exact cause. Reactive airway disease symptoms include, CHRONIC COUGH that clears mucus (sputum) from your airways.

  • Shortness of breath (dyspnea)
  • Difficulty breathing
  • Wheezing
  • Chest Tightness